Skip to main content
Owkin logo

Owkin

Updated Mar 24, 2026

A deep look at Owkin's finances, team, and market position in the AI Healthcare space.

🇫🇷FranceSeries BAI Healthcare

Out of 100

🇫🇷

HQ

France

🗓

Founded

2016

💰

Raised

$354M

🏷️

Stage

Series B

👥

Team

450

Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary

Is this your company? Claim it →

Key Facts

  • Owkin is valued at $1B as of March 2026.
  • Owkin has raised a total of $354M in disclosed funding across 3 funding rounds.
  • Owkin was founded in 2016 by Thomas Clozel and is headquartered in France.
  • Owkin employs approximately 450 people.
  • Owkin operates in the AI Healthcare category and is currently at the Series B stage.
  • Owkin has an Awaira Score of 69/100, ranking it among the tracked AI companies on Awaira.
  • Owkin's most recent funding round was a Series B of $100M closed in January 2021.

Source: Awaira · Updated Mar 24, 2026

$1B

Post-money

$354M

All rounds

69/100

2016

450 employees

Strengths

Strong Awaira Score of 69/100

Growing team of 450 employees

Analysis based on publicly available data. Not investment advice.

3

Total Rounds

$37.83M

Avg Round Size

4.1yr

Funding Span

Owkin raised 3 rounds over 4.1 years, averaging $37.83M per round — a pace of roughly one round every 16 months.

⚠️ ESTIMATE
💵Est. Annual Revenue
$20M–$100M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does Owkin stack up against competitors?

MetricOwkinButterfly NetworkTempusAlan
Awaira Score69/10085/10084/10083/100
Total Raised$354M$370M$1.05B$750M
Valuation$1B$957M$8.1B$5.83B
StageSeries BPublicPublicSeries D
Founded2016201120152016
Employees450500-10002500500-1000
Country🇫🇷🇺🇸🇺🇸🇫🇷
T

Thomas Clozel

Founder & CEO

View founder profile →
StageSeries B
Employees450
Country🇫🇷 France
Connect
Inactive
3 rounds
Series BLatest

Eurazeo, Omnes Capital, Bpifrance

$100M

Jan 2021

Series A

Idinvest Partners, Région Île-de-France

$10M

Jan 2018

Seed

$3.5M

Jan 2017

Frequently Asked Questions

What is Owkin's valuation?
As of its latest round, Owkin carries a valuation of $1B.
Who invested in Owkin?
The investor list includes Eurazeo, Omnes Capital, Bpifrance, Idinvest Partners, Région Île-de-France — a mix that reflects confidence in the AI Healthcare business.
When did Owkin last raise funding?
The most recent round was a Series B of $100M, closed in January 2021.
How many employees does Owkin have?
Around 450 people work there, with headquarters in France.
What does Owkin do?
Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Founded in 2016, Owkin is categorized under AI Healthcare.
Who founded Owkin?
The company was started by Thomas Clozel in 2016 in France. Thomas Clozel serves as Founder & CEO.
Is Owkin profitable?
There's no public reporting on profitability. With raised $354M in total funding, the company remains at the Series B stage.
Where is Owkin headquartered?
Based in France 🇫🇷, the company runs its operations in the AI Healthcare space and was established in 2016.
⚔️

Compare Owkin

See how Owkin stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →